See more : Runjian Co., Ltd. (002929.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Standard BioTools Inc. (LAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Rosebank Industries Plc (ROSE.L) Income Statement Analysis – Financial Results
- Dingli Corp., Ltd. (300050.SZ) Income Statement Analysis – Financial Results
- Angion Biomedica Corp. (ANGN) Income Statement Analysis – Financial Results
- Oxbridge Acquisition Corp. (OXACU) Income Statement Analysis – Financial Results
- PetroChina Company Limited (PTR) Income Statement Analysis – Financial Results
Standard BioTools Inc. (LAB)
About Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.40M | 130.58M |
Cost of Revenue | 55.89M | 60.90M | 61.21M | 54.82M | 52.96M | 51.32M | 49.96M | 46.01M | 46.63M | 42.85M | 20.08M | 15.33M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M | 53.32M |
Gross Profit | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.10M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M | 77.27M |
Gross Profit Ratio | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.80% | 45.50% | 51.70% | 56.66% | 59.17% |
Research & Development | 25.95M | 38.50M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.42M | 39.26M | 43.42M | 19.73M | 16.60M | 13.94M | 13.01M | 12.32M | 14.02M | 14.39M | 15.59M | 37.94M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 87.54M | 114.76M | 98.89M | 97.90M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.06M | 38.48M | 31.30M | 23.55M | 19.65M | 22.51M | 12.90M | 9.70M | 98.89M |
Other Expenses | 0.00 | -12.31M | 7.63M | 507.00K | 1.43M | 637.00K | 385.00K | -1.17M | -1.16M | -857.00K | 502.00K | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89M |
Operating Expenses | 113.49M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.79M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M | 144.73M |
Cost & Expenses | 169.38M | 214.15M | 198.04M | 189.18M | 169.08M | 161.13M | 160.30M | 177.64M | 168.85M | 157.60M | 87.87M | 70.41M | 58.43M | 48.13M | 43.45M | 44.89M | 30.80M | 28.06M | 198.04M |
Interest Income | 0.00 | 4.33M | 291.00K | 307.00K | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 37.00K | 766.00K | 1.14M | 565.00K | 0.00 |
Interest Expense | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14.00K | 628.00K | 3.10M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M | -3.82M |
Depreciation & Amortization | 15.18M | 15.03M | 16.07M | 17.94M | 15.81M | 16.50M | 18.30M | 17.94M | 16.12M | 4.06M | 2.55M | 1.48M | 1.06M | 1.50M | 1.94M | 1.97M | 2.14M | 1.46M | 0.00 |
EBITDA | -54.46M | -173.57M | -43.77M | -34.61M | -46.62M | -31.03M | -39.68M | -56.42M | -32.87M | -38.50M | -13.82M | -16.78M | -18.14M | -13.52M | -14.67M | -26.12M | -20.91M | -19.83M | -67.46M |
EBITDA Ratio | -51.21% | -115.87% | -33.89% | -25.05% | -29.51% | -27.40% | -38.62% | -54.02% | -34.16% | -32.58% | -19.15% | -32.06% | -33.84% | -38.92% | -63.20% | -174.69% | -278.32% | -306.96% | -51.66% |
Operating Income | -76.60M | -116.21M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M | -67.46M |
Operating Income Ratio | -72.03% | -118.64% | -51.66% | -36.94% | -44.22% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.50% | -323.38% | -338.59% | -51.66% |
Total Other Income/Expenses | 2.40M | -76.72M | 3.80M | -3.07M | -14.87M | -13.26M | -5.44M | -6.99M | -4.64M | -5.87M | 2.26M | -817.00K | -3.74M | -2.25M | -1.14M | -103.00K | -1.82M | -1.89M | 3.80M |
Income Before Tax | -74.20M | -192.93M | -63.66M | -54.10M | -66.71M | -61.42M | -63.80M | -80.18M | -54.79M | -57.71M | -15.69M | -18.89M | -22.30M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M | -63.66M |
Income Before Tax Ratio | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.40% | -368.13% | -48.75% |
Income Tax Expense | 452.00K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137.00K | 136.00K | 166.00K | 83.00K | -50.00K | -147.00K | 105.00K | 194.00K | -4.42M |
Net Income | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M | -59.01M | -60.54M | -75.99M | -53.32M | -52.83M | -15.82M | -19.02M | -22.47M | -16.90M | -19.13M | -29.50M | -25.45M | -23.55M | -59.24M |
Net Income Ratio | -70.21% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% | -45.36% |
EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
EPS Diluted | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
Weighted Avg Shares Out | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
Weighted Avg Shares Out (Dil) | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
Standard BioTools Appoints Alex Kim as Chief Financial Officer
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates
Standard BioTools Reports Third Quarter 2024 Financial Results
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024
GENOMMA LAB INTERNACIONAL ANNOUNCES NINTH DIVIDEND PAYMENT
Standard BioTools And 2 Other Penny Stocks Executives Are Buying
Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying
Standard BioTools to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports